Get the Stockscreener App
2.45
2.80%
-0.05
Nkarta Inc stock is traded at $2.45, with a volume of 105.33K.
It is down -2.80% in the last 24 hours and down -42.42% over the past month.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
See More
Previous Close:
$2.50
Open:
$2.48
24h Volume:
105.33K
Relative Volume:
0.16
Market Cap:
$171.83M
Revenue:
-
Net Income/Loss:
$-117.50M
P/E Ratio:
-0.957
EPS:
-2.56
Net Cash Flow:
$-114.31M
1W Performance:
-10.00%
1M Performance:
-42.42%
6M Performance:
-62.79%
1Y Performance:
-3.95%
1-Day Range:
$2.395
$2.51
1-Week Range:
$2.38
$2.735
52-Week Range:
$2.38
$16.24
Nkarta Inc Stock (NKTX) Company Profile
Name
Nkarta Inc
Sector
Industry
Phone
(925) 407-1049
Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| NKTX | 2.45 | 171.83M | 0 | -117.50M | -114.31M | -2.56 |
| VRTX | 447.00 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 739.78 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.30 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.57 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.41 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-14-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-22-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Jul-28-22 | Initiated | Needham | Buy |
| Jul-18-22 | Initiated | SVB Leerink | Outperform |
| Mar-11-22 | Initiated | Raymond James | Outperform |
| Mar-08-22 | Initiated | H.C. Wainwright | Buy |
| Jan-06-22 | Initiated | William Blair | Outperform |
| Nov-18-21 | Initiated | SMBC Nikko | Outperform |
| Jul-16-21 | Initiated | Oppenheimer | Outperform |
| Aug-04-20 | Initiated | Cowen | Outperform |
| Aug-04-20 | Initiated | Evercore ISI | Outperform |
| Aug-04-20 | Initiated | Mizuho | Buy |
| Aug-04-20 | Initiated | Stifel | Buy |
View All
Nkarta Inc Stock (NKTX) Latest News
Nkarta price target lowered to $16 from $20 at Mizuho - TipRanks
NKTX stock touches 52-week low at $2.44 amid market fluctuations - Investing.com UK
Despite Hitting US$2.91, Nkarta Insiders Still Sold Too Soon - Simply Wall St
Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more - BioSpace
Nkarta to Participate in an Upcoming Investor Conference - The Manila Times
Nkarta to Present at Stifel Healthcare Conference: NK Cell Therapy Updates Expected | NKTX Stock News - StockTitan
Nkarta (NASDAQ:NKTX) Price Target Cut to $18.00 by Analysts at HC Wainwright - MarketBeat
Nkarta (NASDAQ:NKTX) Given New $11.00 Price Target at Needham & Company LLC - MarketBeat
Nkarta, Inc. Reports Q3 2024 Financial Results - TipRanks
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights - GlobeNewswire
Nkarta, Inc. (NASDAQ:NKTX) Receives $17.50 Average PT from Brokerages - Defense World
Brokerages Set Nkarta, Inc. (NASDAQ:NKTX) Price Target at $17.50 - MarketBeat
Nkarta (NKTX) Stock: Looking For Upside - Seeking Alpha
Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade) - Seeking Alpha
SG Americas Securities LLC Purchases New Shares in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Bleakley Financial Group LLC Has $69,000 Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth - Yahoo Finance
GAMMA Investing LLC Increases Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Are Nkarta Inc (NKTX) shares a good deal now? - US Post News
Daily Market Movement: Nkarta Inc (NKTX) Sees a 1.29 Increase, Closing at 3.94 - The Dwinnex
Nkarta, Inc. (NASDAQ:NKTX) Shares Bought by Dimensional Fund Advisors LP - Defense World
AQR Capital Management LLC Invests $938,000 in Nkarta, Inc. (NASDAQ:NKTX) - MarketBeat
Nkarta Inc (NKTX) Stock: A Year of Market Fluctuations - The InvestChronicle
Nkarta (NASDAQ:NKTX) Stock Rating Upgraded by RODMAN&RENSHAW - Defense World
Nkarta (NASDAQ:NKTX) Upgraded to "Strong-Buy" by RODMAN&RENSHAW - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Nkarta (NASDAQ:NKTX) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat
Raymond James upgrades Nkarta Inc (NKTX) stock to a Strong buy - Knox Daily
Nkarta upgraded at Raymond James on valuation - MSN
A History of Outperforming Analyst Forecasts and Beating the Odds: Nkarta Inc (NKTX) - SETE News
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - Benzinga
Metric Analysis: Nkarta Inc (NKTX)’s Key Ratios in the Limelight - The Dwinnex
Nkarta Inc (NKTX) stock on the rise: An overview - US Post News
American Century Companies Inc. Has $427,000 Stake in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Anchoring Your Portfolio: Is NKTX Stock a Safe Harbor? - The InvestChronicle
Marshall Wace LLP Grows Stake in Nkarta, Inc. (NASDAQ:NKTX) - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Shares Bought by Marshall Wace LLP - Defense World
It makes sense and dollars to buy Nkarta Inc (NKTX) stock - SETE News
Cubist Systematic Strategies LLC Invests $1.49 Million in Nkarta, Inc. (NASDAQ:NKTX) - MarketBeat
Nkarta Inc (NKTX) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Nkarta's SWOT analysis: NK cell therapy stock shows promise amid risks - Investing.com India
Forefront Analytics LLC Invests $70,000 in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Renaissance Technologies LLC Acquires 98,000 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta Inc [NASDAQ: NKTX] Sees Decrease in Stock Value - Knox Daily
Nkarta, Inc. (NASDAQ:NKTX) Shares Sold by Deerfield Management Company L.P. Series C - MarketBeat
Rhumbline Advisers Acquires 33,117 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Affinity Asset Advisors LLC Purchases New Shares in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Affinity Asset Advisors LLC Takes Position in Nkarta, Inc. (NASDAQ:NKTX) - MarketBeat
Wall Street analysts’ outlook for Nkarta Inc (NKTX) - SETE News
Nkarta Inc (NKTX)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Market Momentum Report: Nkarta Inc (NKTX)’s Negative Close at 5.21 - The Dwinnex
Nkarta Inc Stock (NKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nkarta Inc Stock (NKTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Trager James | Chief Scientific Officer |
Jun 18 '24 |
Sale |
5.60 |
456 |
2,554 |
150,959 |
| HASTINGS PAUL J | Chief Executive Officer |
Jun 18 '24 |
Sale |
5.60 |
1,770 |
9,912 |
240,737 |
| Shook David | Chief Medical Officer |
Jun 18 '24 |
Sale |
5.60 |
456 |
2,554 |
116,524 |
| Hager Alicia J. | Chief Legal Officer |
Jun 18 '24 |
Sale |
5.60 |
727 |
4,071 |
107,215 |
| Brandenberger Ralph | Chief Technical Officer |
Jun 18 '24 |
Sale |
5.60 |
229 |
1,282 |
79,743 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 27 '24 |
Buy |
10.00 |
3,000,000 |
30,000,000 |
10,050,818 |
| George Simeon | Director |
Mar 27 '24 |
Buy |
10.00 |
2,000,000 |
20,000,000 |
1,548,341 |
| Brandenberger Ralph | Chief Technical Officer |
Mar 01 '24 |
Option Exercise |
3.89 |
6,763 |
26,308 |
88,339 |
| Brandenberger Ralph | Chief Technical Officer |
Mar 01 '24 |
Sale |
12.51 |
8,367 |
104,671 |
79,972 |
| Trager James | Chief Scientific Officer |
Feb 12 '24 |
Sale |
12.00 |
4,143 |
49,716 |
149,415 |
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):